Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

Specimen Handling 6Colposcopy 5Human Papillomavirus DNA Tests 4fludarabine phosphate 2fludarabine 2aldesleukin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Cyclophosphamide 2polyphenon E 1human papillomavirus vaccine, L1 type 16, 18 1adacel 1Vaginal Smears 1Tetanus Toxoid 1Respiratory Function Tests 1Radiotherapy 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Imaging 1Loperamide 1Ipilimumab 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Granisetron 1Electrocardiography 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Papillomavirus Infections × Hydroxyzine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡